Pilot Study to Determine if Working Memory Training Aids Cognitive Functioning in Patients With Parkinson's Disease (PDWM)

May 18, 2023 updated by: Gail Eskes

Beyond the Physical: Enhancing Psychosocial Functioning in Parkinson's Disease

This project will investigate the feasibility and preliminary effectiveness of an intensive and focused working memory training program for patients in the early stages of PD receiving dopaminergic therapy. The investigators hypothesize that working memory training will be an effective method of improving working memory and related cognitive and behavioural functions in PD patients.

Study Overview

Detailed Description

Parkinson's disease (PD) is not an exclusively motor disease; more than half of individuals with PD experience cognitive impairment even in the early stages of the disease and many develop dementia as the disease progresses. As a result, attention, memory, planning and organizational skills can be affected, interfering with everyday functioning (e.g. shopping, managing finances, job skills). Thus, interventions to improve cognitive abilities are needed to enhance psychosocial function and overall quality of life.

Some cognitive deficits, such as problems with working memory, are apparent even in the early stages of the disease. Working memory (WM) is the ability to actively maintain and manipulate information in one's mind and is needed for many complex tasks such as learning, communication and problem-solving . Individuals with PD often show deficits in both WM maintenance (e.g., holding a phone number in mind to make a call) and manipulation (e.g.,mental calculation at the grocery store checkout) skills, depending upon the stage of the disease and progression of damage to frontal-subcortical circuits. Attempts to identify pharmacological agents that ameliorate cognitive dysfunction have been largely unsuccessful or associated with undesirable side effects (e.g. Vale, 2009).

The investigators propose that specific cognitive training to improve WM could provide direct benefit to psychosocial function of PD patients; it could potentially enhance any positive benefits or reduce the negative effects of pharmacological treatment without an added risk of side effects as well. Promising interventions focused on intensive and direct WM training are emerging and have been shown to generalize to other cognitive domains, such as fluid intelligence.

Cognitive training has been successful in patients with traumatic brain injury, who also show WM deficits as a result of damage to frontal-subcortical circuits. In addition, successful WM training is associated with changes in dopamine receptor density as well as changes in patterns of neural activity in task-relevant areas of the brain. To date, a limited number of small group studies provide preliminary evidence that some aspects of cognitive function can be enhanced by training in PD patients also receiving dopaminergic therapy, although few use control groups to account for potential repeated testing practice effects.

Study Type

Interventional

Enrollment (Anticipated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Nova Scotia
      • Halifax, Nova Scotia, Canada
        • Dalhousie University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • clinical diagnosis of idiopathic Parkinson's disease
  • self-reported concerns about their working memory, or working memory deficits that were identified by a clinical examination
  • be classified as Hohn & Yahr Stage 1 or 2
  • be receiving a stable dose of dopaminergic therapy

Exclusion Criteria:

  • presence of dementia or other significant neurological or psychiatric conditions, as determined by clinical history
  • Classification as Hohm & Yahr Stage 3 or 4
  • Not on a stable dos of dopaminergic therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Early training group
The early training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. They will continue training on the adaptive working memory training task for 5 weeks, after which they will continue for 5 weeks using a non-adaptive working memory task (active control task).

The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.

Adaptive refers to the increase in the number of items that the patient is required to remember.

Active control task will consist of a non-adaptive working memory task.
Experimental: Late training group
The late training group will consist of 10 randomly assigned participants who will engage in a non-adaptive working memory training task (i.e. an active control task) immediately after baseline assessment for 5 weeks. After the initial 5 weeks of the active control task they will then switch to the adaptive working memory task (the intervention) for 5 weeks. This is a randomized controlled cross-over design.

The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.

Adaptive refers to the increase in the number of items that the patient is required to remember.

Active control task will consist of a non-adaptive working memory task.
Placebo Comparator: No training group
The no training group will engage in no training over the course of the pilot study, but will still participate in baseline, 5 week, 10 . This will allow us to determine if changes in the outcome and assessment variables are due to the working memory training or progression in the disease itself.
No training during the experiment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline Working memory function
Time Frame: baseline

Working memory will be measured using the operation span task, the symmetry span task and the Sternberg memory scanning tasks.

Operation span - This is a dual-task in which participants complete mathematical reasoning (e.g. solving a mathematical equation) while using short-term verbal memory to remember words.

Symmetry span: This is a dual task in which participants discriminate about the symmetry of visual stimuli while using short-term spatial memory to remember the locations of stimuli.

Sternberg memory scanning task - number memory test

baseline
Change in working memory function between baseline and 5 weeks post training onset
Time Frame: 5 weeks post training onset
5 weeks post training onset
Change in working memory function between baseline and 10 weeks post training onset
Time Frame: 10 weeks post training onset
10 weeks post training onset
Change in working memory function between baseline and 22 weeks post training onset
Time Frame: 22 weeks post training onset
22 weeks post training onset

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline fluid intelligence
Time Frame: Baseline
Fluid intelligence will be measured using Cattell's Culture Fair Intelligence Test, a measure of analogical reasoning, and Raven's Progressive Matrices, a measure of spatial reasoning.
Baseline
change in fluid intelligence between baseline and 5 weeks post training onset
Time Frame: 5 weeks post training onset
5 weeks post training onset
Change in fluid intelligence between baseline and 10 weeks post training onset
Time Frame: 10 weeks post training onset
10 weeks post training onset
Change in fluid intelligence between baseline and 22 weeks post training onset
Time Frame: 22 weeks post training onset
22 weeks post training onset
Baseline Executive functioning
Time Frame: Baseline
Executive functioning will be measured using the Dysexecutive Questionnaire. It is a self-report and other-report of everyday behaviours reflecting executive function.
Baseline
Change in executive functioning between baseline and 5 weeks post training onset
Time Frame: 5 weeks post training onset
5 weeks post training onset
Change in executive functioning between baseline and 10 weeks post training onset
Time Frame: 10 weeks post training onset
10 weeks post training onset
Change in executive function between baseline and 22 weeks post training onset
Time Frame: 22 weeks post training onset
22 weeks post training onset

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Gail Eskes, PhD, Dalhousie University
  • Study Chair: Raymond Klein, PhD, Dalhousie University
  • Study Chair: David Westwood, PhD, Dalhousie University
  • Principal Investigator: Stephanie Jones, PhD, Dalhousie University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2013

Primary Completion (Anticipated)

December 31, 2024

Study Completion (Anticipated)

December 31, 2024

Study Registration Dates

First Submitted

July 13, 2012

First Submitted That Met QC Criteria

July 19, 2012

First Posted (Estimate)

July 23, 2012

Study Record Updates

Last Update Posted (Actual)

May 19, 2023

Last Update Submitted That Met QC Criteria

May 18, 2023

Last Verified

May 1, 2023

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on Adaptive working memory training task

Subscribe